Filing Details
- Accession Number:
- 0001242616-12-000017
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-08-07 16:13:17
- Reporting Period:
- 2012-08-06
- Filing Date:
- 2012-08-07
- Accepted Time:
- 2012-08-07 16:13:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
792977 | Amag Pharmaceuticals Inc. | AMAG | Pharmaceutical Preparations (2834) | 042742593 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1408474 | Phd Md F Lee Allen | C/O Amag Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421 | Evp, Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-08-06 | 5,000 | $0.00 | 7,229 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2012-08-06 | 5,000 | $0.00 | 2,229 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Acquisiton | 2012-08-06 | 5,000 | $0.00 | 5,000 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
5,000 | No | 4 | C | Direct |
Footnotes
- The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below.
- Not applicable.
- The shares sold on this date were sold in multiple transactions. The actual sales prices range from $15.67-$15.745. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
- Each restricted stock unit represents a contingent right to receive one share of common stock.
- Grant of 20,000 restricted stock units pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vested as follows: 50% on August 5, 2010, 25% on August 5, 2011 and the remaining 25% on August 5, 2012.